Loading
Edesa Biotech, Inc. is a biopharmaceutical firm focused on discovering, developing, and commercializing clinical-stage treatments for inflammatory and immune system disorders where current medical options are inadequate. The company's key pipeline assets include EB05, a monoclonal antibody undergoing a Phase 3 clinical trial for acute respiratory distress syndrome (ARDS) in COVID-19 patients, and EB01, a topical therapy in a Phase 2B clinical study addressing chronic allergic contact dermatitis. Furthermore, Edesa has a licensing collaboration with NovImmune SA to advance monoclonal antibodies specifically designed to target TLR4 and CXCL10. This company was established in 2015 and is based in Markham, Canada.
Previous close
$3.51
−$0.15 · -4.10%
Regular session · ET · Market data may be delayed.
Edesa Biotech, Inc. is a biopharmaceutical firm focused on discovering, developing, and commercializing clinical-stage treatments for inflammatory and immune system disorders where current medical options are inadequate. The company's key pipeline assets include EB05, a monoclonal antibody undergoing a Phase 3 clinical trial for acute respiratory distress syndrome (ARDS) in COVID-19 patients, and EB01, a topical therapy in a Phase 2B clinical study addressing chronic allergic contact dermatitis. Furthermore, Edesa has a licensing collaboration with NovImmune SA to advance monoclonal antibodies specifically designed to target TLR4 and CXCL10. This company was established in 2015 and is based in Markham, Canada.
Day range
Current $3.51
52-week range
Current $3.51
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
29
Expensive
Sentiment
64
Bullish
Risk
69
High Risk
Momentum
45
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Edesa Biotech, Inc. is a biopharmaceutical firm focused on discovering, developing, and commercializing clinical-stage treatments for inflammatory and immune system disorders where current medical options are inadequate. The company's key pipeline assets include EB05, a monoclonal antibody undergoing a Phase 3 clinical trial for acute respiratory distress syndrome (ARDS) in COVID-19 patients, and EB01, a topical therapy in a Phase 2B clinical study addressing chronic allergic contact dermatitis. Furthermore, Edesa has a licensing collaboration with NovImmune SA to advance monoclonal antibodies specifically designed to target TLR4 and CXCL10. This company was established in 2015 and is based in Markham, Canada.
Day range
Current $3.51
52-week range
Current $3.51
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | 119.27K USD | — | — | — | 118.79K USD |
| Gross profit | −119.27K USD | — | — | — | −118.79K USD |
| Research and development | 3.67M USD | 2.88M USD | 4.79M USD | 13.34M USD | 17.95M USD |
| Selling, general, and administrative | 4.24M USD | 4.13M USD | 4.43M USD | 5.04M USD | 5.73M USD |
| Operating expenses | 7.79M USD | 7.01M USD | 9.22M USD | 18.37M USD | 23.68M USD |
| Interest income | 2.56K USD | 153.5K USD | 289.85K USD | 63.52K USD | 11.17K USD |
| Depreciation and amortization | 119.27K USD | 186.05K USD | 183.47K USD | 118.19K USD | 118.79K USD |
| Operating income | −7.91M USD | −7.01M USD | −9.22M USD | −18.37M USD | −23.68M USD |
| Net income | −7.19M USD | −6.17M USD | −8.37M USD | −17.55M USD | −13.34M USD |
Company facts updated Oct 10, 2026.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Oct 11, 2023 | 1:7 | — | — |
Stock split | Jun 10, 2019 | 1:6 | — | — |
Stock split | May 7, 2018 | 1:7 | — | — |
Stock split | Sep 2, 2015 | 1:10 | — | — |
Effective Oct 11, 2023
1:7
Effective Jun 10, 2019
1:6
Effective May 7, 2018
1:7
Effective Sep 2, 2015
1:10
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
